101. The PP2A inhibitor LB-100 mitigates lupus nephritis by suppressing tertiary lymphoid structure formation.
- Author
-
Yang H, Luo X, Wang X, Peng Y, Li Z, He Y, Cong J, Xie T, and Zhang W
- Subjects
- Animals, Mice, Female, Mice, Inbred MRL lpr, Kidney drug effects, Kidney pathology, Kidney metabolism, Disease Models, Animal, Spleen drug effects, Spleen pathology, Spleen immunology, Enzyme Inhibitors pharmacology, Enzyme Inhibitors therapeutic use, Piperazines, Protein Phosphatase 2 antagonists & inhibitors, Protein Phosphatase 2 metabolism, Lupus Nephritis drug therapy, Lupus Nephritis pathology, Tertiary Lymphoid Structures pathology, Mice, Inbred BALB C
- Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multi-organ involvement and autoantibody production. Patients with SLE face a substantial risk of developing lupus nephritis (LN), which imposes a substantial burden on both patients and their families. Protein phosphatase 2A (PP2A) is a widely distributed serine/threonine phosphatase that participates in regulating multiple signaling pathways. Inhibition of PP2A has been implicated in the treatment of various diseases. LB-100, a small molecule inhibitor of PP2A, has demonstrated anti-tumor therapeutic effects and high safety profile in preclinical experiments. However, the role of PP2A and its inhibitor has been insufficiently studied in LN. In this study, we assessed the potential effects of LB-100 in both MRL/lpr mice and R848-induced BALB/c mice. Our findings indicated that LB-100 administration led to reduced spleen enlargement, decreased deposition of immune complexes, ameliorated renal damage, and improved kidney function in both spontaneous and R848-induced lupus mouse models. Importantly, we observed the formation of tertiary lymphoid structures (TLSs) in the kidneys of two distinct lupus mouse models. The levels of signature genes of TLS were elevated in the kidneys of lupus mice, whereas LB-100 mitigated chemokine production and inhibited TLS formation. In addition, we confirmed that inhibition or knockdown of PP2A reduced the production of T cell-related chemokines by renal tubular epithelial cells (RTEC). In summary, our study highlighted the renal protective potential of the PP2A inhibitor LB-100 in two distinct lupus mouse models, suggesting its potential as a novel strategy for treating LN and other autoimmune diseases., Competing Interests: Declaration of competing interest The authors state that they do not possess any recognized conflicting financial interests or personal ties that could have potentially impacted the findings provided in this research., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF